Abstract:Background MicroRNAs, as small non-coding RNAs, play an important role in tumorigenesis. MiR-483-5p was found to have a significant increase as a diagnostic biomarker of nasopharyngeal carcinoma (NPC), not only in plasma from NPC patients but also in tumor cell lines and biopsy tissues in our previous study. However, its function and mechanism in NPC are still unclear. Methods Tissue microarray including 178 primary NPC and 35 adjacent non-cancerous nasopharyngeal mucosal tissues was used to further validate the overexpression of miR-483-5p. Wound healing and invasion assays were conducted to verify its biological function. RNA sequencing (RNA-seq) and dual-luciferase reporter assay was performed to explore its target, and it was verified in fresh biopsy tissues from 23 NPC patients and 9 patients with chronic nasopharyngitis. Results MiR-483-5p was highly expressed in NPC tissues than in adjacent non-cancerous tissues. It was found to have a significant correlation with poor overall survival (OS) [hazard ratio (HR) = 2.89, 95% confidence interval (CI) = 1.00–8.35, p = 0.041] and progression-free survival (PFS) (HR = 1.95, 95%CI = 1.06–3.60, p = 0.029) of NPC patients. Silencing of its expression inhibited the migratory and invasive capacities of NPC cells in vitro . EGR3 (early growth response 3) was identified as a direct target, and inhibiting miR-483-5p expression markedly enhanced the expression of EGR3 at both the mRNA and protein levels. Besides, a significant decrease of EGR3 expression was found in fresh biopsy tissues from NPC patients, in contrast to miR-483-5p expression. Furthermore, directly decreasing the expression of EGR3 could enhance the migration and invasion of NPC cells. Conclusion The newly identified miR-483-5p/ EGR3 pathway provides further insights into the development and metastasis of NPC and may provide a potential therapeutic target for NPC treatment in order to improve survival of NPC patients.

MiR-223 Inhibits the Proliferation, Invasion and EMT of Nasopharyngeal Carcinoma Cells by Targeting SSRP1

MiR-223 Targeting MAFB Suppresses Proliferation and Migration of Nasopharyngeal Carcinoma Cells

miR-29a/b Enhances Cell Migration and Invasion in Nasopharyngeal Carcinoma Progression by Regulating SPARC and COL3A1 Gene Expression

Mir-18A Downregulates DICER1 and Promotes Proliferation and Metastasis of Nasopharyngeal Carcinoma.

MiR-663, a Microrna Targeting P21waf1/cip1, Promotes the Proliferation and Tumorigenesis of Nasopharyngeal Carcinoma

miR-185-3p regulates the invasion and metastasis of nasopharyngeal carcinoma by targeting WNT2B in vitro .

Mir-9 Targets CXCR4 and Functions As a Potential Tumor Suppressor in Nasopharyngeal Carcinoma.

MicroRNA-432 Suppresses Invasion and Migration Via E2F3 in Nasopharyngeal Carcinoma

Mir-324-3p Suppresses Migration and Invasion by Targeting WNT2B in Nasopharyngeal Carcinoma.

The Effects of Microrna-98 Inhibits Cell Proliferation and Invasion by Targeting STAT3 in Nasopharyngeal Carcinoma.

Microrna-152 Inhibits Cell Proliferation, Migration and Invasion by Directly Targeting Mafb in Nasopharyngeal Carcinoma

MicroRNA-338 inhibits migration and proliferation by targeting hypoxia-induced factor 1 alpha in nasopharyngeal carcinoma

miRNA‐22‐3p inhibits cell viability and metastasis of nasopharyngeal carcinoma by targeting FOXP1

Ott_a_233435 11271..11280

Ceruloplasmin Inhibits the Proliferation, Migration and Invasion of Nasopharyngeal Carcinoma Cells and is Negatively Regulated by Mir-543

MicroRNA-483-5p Predicts Poor Prognosis and Promotes Cancer Metastasis by Targeting EGR3 in Nasopharyngeal Carcinoma

MiR-24 functions as a tumor suppressor in nasopharyngeal carcinoma through targeting FSCN1

miR-26a-5p suppresses nasopharyngeal carcinoma progression by inhibiting PTGS2 expression

miR-137 Inhibition of the Invasion, Metastasis, and Epithelial-Mesenchymal Transition of Nasopharyngeal Cancer by Regulating KDM1A

MicroRNA-215 promoted the progression of nasopharyngeal carcinoma through targeting RB1 and activating Wnt/β-catenin pathway.

miR-212-5p inhibits nasopharyngeal carcinoma progression by targeting METTL3